Acute pancreatitis associated with liraglutide

Annals of Pharmacotherapy

Volumn 45, Issue 4, 2011, Pages

  Lee, Phillip H ^a   Stockton, M David ^b   Franks, Andrea S ^b  

^a UNIVERSITY OF TENNESSEE MEDICAL CENTER   (United States)

^b UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE   (United States)

Author keywords

Drug induced pancreatitis; Glucagon like peptide 1 agonist; Glucagonlike peptide 1 analogue; Liraglutide; Pancreatitis

Indexed keywords

EXENDIN 4; LIRAGLUTIDE; TRIACYLGLYCEROL LIPASE;

ACUTE PANCREATITIS; ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; EPIGASTRIC PAIN; FEMALE; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; TRIACYLGLYCEROL LIPASE BLOOD LEVEL;

ACUTE DISEASE; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; LIPASE; MIDDLE AGED; PANCREATITIS; PEPTIDES; VENOMS;

EID: 79955550099     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P714     Document Type: Article

References (17)

1. Badalov N, Baradarian R, Iswara K, Li J, Steinberg W, Tenner S. Druginduced acute pancreatitis: an evidence-based review. Clin Gastroenterol Hepatol 2007;5:648-61.
2. Balani AR, Grendell JH. Drug-induced pancreatitis: incidence, management and prevention. Drug Saf 2008;31:823-37.
3. Neumiller JJ, Campbell RK. Liraglutide: a once-daily incretin mimetic for the treatment of type 2 diabetes mellitus. Ann Pharmacother 2009; 43:1433-44. DOI 10.1345/aph.1M134
4. Joffe D. Liraglutide: a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes mellitus. Am J Health Syst Pharm 2010;67: 1326-36. DOI 10.2146/ajhp090230
5. Anderson SL, Trujillo JM. Association of pancreatitis with glucagon-like peptide-1 agonist use. Ann Pharmacother 2010;44:904-9. DOI 10.1345/aph.1M676
6. Marre M, Shaw J, Brändle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26:268-78.
7. Nauck M, Frid A, Hermansen K, et al. LEAD-2 study group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009;32:84-90. DOI 10/2337/dc08-13255
8. Garber A, Henry R, Ratner R, et al. LEAD-3 (Mono) study group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373:473-81. DOI 10.1016/S0140-6736(08)61246-5
9. Zinman B, Gerich J, Buse JB, et al. LEAD-4 study investigators. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009;32:1224-30. DOI 10.2337/dc08-2124
10. Russell-Jones D, Vaag A, Schmitz O, et al. LEAD-5 study group. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009;52:2046-55. DOI 10.1007/s00125-009-1472-y
11. Buse JB, Rosenstock J, Sesti G, et al. LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47. DOI 10.1016/S0140-6736(09)60659-0
12. Package insert. Victoza (liraglutide). Princeton, NJ: Novo Nordisk, December 22, 2010.
13. Data on file. Princeton, NJ: Novo Nordisk, January 6, 2011.
14. FDA brief report. Liraglutide (injection) NDA 22-341. Endocrine and Metabolic Drug Advisory Committee. Novo Nordisk, April 2, 2009. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM148659.pdf (accessed 2011 Jan 6).
15. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
16. Buse JB, Sesti G, Schmidt WE, et al. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care 2010:33:1300-3.
17. Noel R, Braun D, Patterson R, Bloomgren G. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 2009;32:834-8. DOI 10.2337/dc08-1755